
Please try another search
As per the transaction announced on January 30, 2025, Opsy Holding AB was acquired by OPSY AB, in a reverse merger transaction. Opsy Holding AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. Opsy Holding AB was formerly known as WntResearch AB and changed its name to Opsy Holding AB in April 2025. The company was incorporated in 2007 and is based in Lund, Sweden.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review